nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-183-11-113-117nogr-1483Research ArticleОБЗОРREVIEWСовременная нутригеномика и нутригенетика и некоторые метаболические аспекты патогенеза при воспалительных заболеваниях кишечника: взгляд в будущееModern nutrigenomics and nutrigenetics and some metabolic aspects of pathogenesis in inflammatory bowel diseases: a look into the futureПершкоА. М.PershkoA. M.

Першко Анатолий Михайлович, д. м. н., профессор 2 кафедры (терапии усовершенствования врачей)

194044, Санкт-Петербург, улица Академика Лебедева, д. 6

Anatoly M. Pershko, M.D., D. Sc. (Medicine), Professor of 2nd Therapy department of postgraduate education

194044, St. Petersburg, Akademika Lebedev street, 6

pershkoam@mail.ruЯровенкоИ. И.YarovenkoI. I.

Яровенко Ирина Ильинична, к. м. н., доцент, заведующая гастроэнтерологическим отделением клиники 2 кафедры (терапии усовершенствования врачей)

194044, Санкт-Петербург, улица Академика Лебедева, д. 6

Irina I. Yarovenko, Ph.D., associate professor, head of the gastroenterology department of the clinic of 2nd Therapy department of postgraduate education

194044, St. Petersburg, Akademika Lebedev street, 6

ФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» МО РФРоссияMilitary Medical Academy named after S. M. KirovRussian Federation20201411202018311113117Copyright © Першко А.М., Яровенко И.И., 20202020Першко А.М., Яровенко И.И.Pershko A.M., Yarovenko I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1483

Реализация целевой установки терапии воспалительных заболеваниях кишечника — достижение клинико-эндоскопической ремиссии в каждом конкретном случае, даже с учетом препаратов биологической терапии, не всегда достижима. Очевиден тот факт, что пациенты с язвенным колитом и болезнью Крона по своей природе являются генетически неоднородными, что проявляется формированием разных клинико-генетических фенотипов и разнообразных профилей измененной кишечной микробиоты. Современная диетология и нутрициология могут явится важнейшим инструментом тонкой настройки в этой цепи событий и существенным образом повысить эффективность проводимой терапии, в равной мере, способствуя, как нормализации микробного сообщества кишечника, так и, обеспечивая механизмы регулирования экспрессии генов (эпигенетическое воздействие).

The implementation of the target setting for the treatment of inflammatory bowel diseases — the achievement of clinical and endoscopic remission in each case, even taking into account biological therapy drugs, is not always achievable. It is obvious that patients with ulcerative colitis and Crohn’s disease are genetically heterogeneous in nature, which is manifested by the formation of various clinical and genetic phenotypes and various profiles of altered intestinal microbiota. Modern dietetics and nutritionology can be the most important fine-tuning tool in this chain of events and significantly increase the effectiveness of the therapy, equally contributing to both normalization of the intestinal microbial community and providing mechanisms for regulating gene expression (epigenetic effect).

воспалительные заболевания кишечниканутригеномиканутригенетикаinflammatory bowel diseasenutrigenomicsnutrigeneticsReferencesAnnese V., Lombardi G., Perri F. et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease – an IG-IBD study. Am. J. Gastroenterol. 2005, Vol.100, pp.84–92.Annese V., Lombardi G., Perri F. et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease – an IG-IBD study. Am. J. Gastroenterol. 2005, Vol.100, pp.84–92.Annese V., Piepoli A., Latiano A. et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon Rectum, 2005, Vol.48, pp.57–65.Annese V., Piepoli A., Latiano A. et al. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon Rectum, 2005, Vol.48, pp.57–65.Brotherton C. S., Martin C. A., Long M. D. et al. Avoidance of fiber is associated with greater risk of Crohn’s disease flare in a 6-month period. Clin. Gastroenterol. Hepatol, 2016, Vol.14, pp.1130–6.Brotherton C. S., Martin C. A., Long M. D. et al. Avoidance of fiber is associated with greater risk of Crohn’s disease flare in a 6-month period. Clin. Gastroenterol. Hepatol, 2016, Vol.14, pp.1130–6.Calder P. C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br. J. Clin. Pharmacol. 2013;75(3):645–662.Calder P. C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br. J. Clin. Pharmacol. 2013;75(3):645–662.Ferguson L. R. Nutrigenetics, Nutrigenomics and Inflammatory Bowel Diseases. Expert Rev. Clin. Immunol. 2013. Vol 9, pp.735–747.Ferguson L. R. Nutrigenetics, Nutrigenomics and Inflammatory Bowel Diseases. Expert Rev. Clin. Immunol. 2013. Vol 9, pp.735–747.Gentschew L., Bishop K. S., Han D. Y. et al. Selenium, selenoprotein genes and Crohn’s disease in a case–control population from Auckland, New Zealand. Nutrients, 2012, Vol. 4, pp.1247–1259.Gentschew L., Bishop K. S., Han D. Y. et al. Selenium, selenoprotein genes and Crohn’s disease in a case–control population from Auckland, New Zealand. Nutrients, 2012, Vol. 4, pp.1247–1259.Gevers D., Kugathasan S., Denson L. A., et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe, 2014, Vol.15, pp.382–92.Gevers D., Kugathasan S., Denson L. A., et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe, 2014, Vol.15, pp.382–92.Griffin I. J., Kim S. C., Hicks P. D. et al. Zinc metabolism in adolescents with Crohn’s disease. Pediatr. Res. 2004;56(2):235–239.Griffin I. J., Kim S. C., Hicks P. D. et al. Zinc metabolism in adolescents with Crohn’s disease. Pediatr. Res. 2004;56(2):235–239.Guerreiro C. S., Ferreira P., Tavares L., et al. Fatty acids and TNFalpha polymorphisms: an example of nutrigenetics in Crohn’s disease. Am. J. Gastroenterol. 2009, Vol.104, pp. 2241–2249.Guerreiro C. S., Ferreira P., Tavares L., et al. Fatty acids and TNFalpha polymorphisms: an example of nutrigenetics in Crohn’s disease. Am. J. Gastroenterol. 2009, Vol.104, pp. 2241–2249.Hering N. A., Schulzke J. D. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig. Dis. 2009; 27(4):450–454.Hering N. A., Schulzke J. D. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig. Dis. 2009; 27(4):450–454.Jostins L, Ripke S, Weersma RK, et al. Host–microbe interactions have shaped the genetic architecture of infl ammatory bowel disease. Nature. 2012, Vol. 491, pp. 119‐ 124.Jostins L, Ripke S, Weersma RK, et al. Host–microbe interactions have shaped the genetic architecture of infl ammatory bowel disease. Nature. 2012, Vol. 491, pp. 119‐ 124.Kobayashi K. S., Chamaillard M., Ogura Y., Henegariu O. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005, Vol.307, pp.731–34.Kobayashi K. S., Chamaillard M., Ogura Y., Henegariu O. et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005, Vol.307, pp.731–34.Lavoie S., Conway K., Lassen K. еt al. The Crohn’s disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. RESEARCH ARTICLE. 2019. Vol. 22.Lavoie S., Conway K., Lassen K. еt al. The Crohn’s disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. RESEARCH ARTICLE. 2019. Vol. 22.Lee G., Buchman A. DNA-driven nutritional therapy of inflammatory bowel disease. Nutrition. 2009, Vol.25, no.9, pp.885–891.Lee G., Buchman A. DNA-driven nutritional therapy of inflammatory bowel disease. Nutrition. 2009, Vol.25, no.9, pp.885–891.Liefferinckx C., Franchimont D. Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. 2018, Vol. 24, no. 7, pp.1428–1439.Liefferinckx C., Franchimont D. Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. 2018, Vol. 24, no. 7, pp.1428–1439.Liu J. Z., van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet, 2015, Vol. 47, pp.979‐ 986.Liu J. Z., van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet, 2015, Vol. 47, pp.979‐ 986.Molodecky N. A. et al. Increasing incidence and prevalence of the infl ammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012, Vol.142, pp.46–54.Molodecky N. A. et al. Increasing incidence and prevalence of the infl ammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012, Vol.142, pp.46–54.Pazmandi J., Kalinichenko A., Ardy R. C., Boztug K. Earlyonset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunological Reviews. 2019, Vol.287, no.1.Pazmandi J., Kalinichenko A., Ardy R. C., Boztug K. Earlyonset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunological Reviews. 2019, Vol.287, no.1.Petermann I., Triggs C., Claudia Huebner C. et al. Mushroom intolerance: a novel diet–gene interaction in Crohn’s disease. Br. J. Nutr. 2009;102(4):506–508.Petermann I., Triggs C., Claudia Huebner C. et al. Mushroom intolerance: a novel diet–gene interaction in Crohn’s disease. Br. J. Nutr. 2009;102(4):506–508.Petnicki-Ocwieja T., Hrncir T., Liu Y-J., Biswas A. et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc. Natl. Acad. Sci. USA. 2009, Vol.106, pp.15813–18.Petnicki-Ocwieja T., Hrncir T., Liu Y-J., Biswas A. et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc. Natl. Acad. Sci. USA. 2009, Vol.106, pp.15813–18.Pinedo P.J., Buergelt C. D., Donovan G. A. et al. Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle. Vet. Microbiol, 2009, Vol.134, pp.346–52.Pinedo P.J., Buergelt C. D., Donovan G. A. et al. Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle. Vet. Microbiol, 2009, Vol.134, pp.346–52.Rayman M. P. Selenium and human health. Lancet. 2012;379(9822):1256–1262.Rayman M. P. Selenium and human health. Lancet. 2012;379(9822):1256–1262.Ringstad J., Kildebo S., Thomassen Y. Serum selenium, copper, and zinc concentrations in Crohn’s disease and ulcerative colitis. Scand. J. Gastroenterol, 1993;28(7):605–608.Ringstad J., Kildebo S., Thomassen Y. Serum selenium, copper, and zinc concentrations in Crohn’s disease and ulcerative colitis. Scand. J. Gastroenterol, 1993;28(7):605–608.Rooks M. G., Garrett W. S. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol, 2016, Vol.16, pp.341–52.Rooks M. G., Garrett W. S. Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol, 2016, Vol.16, pp.341–52.Silverberg М. S. OCTNs: Will the Real IBD5 Gene Please Stand Up? World J. Gastroenterol, 2006, Vol. 21, pp. 3678–81.Silverberg М. S. OCTNs: Will the Real IBD5 Gene Please Stand Up? World J. Gastroenterol, 2006, Vol. 21, pp. 3678–81.Suzuki T., Hara H. Role of flavonoids in intestinal tight junction regulation. J. Nutr. Biochem. 2011;22(5):401–408.Suzuki T., Hara H. Role of flavonoids in intestinal tight junction regulation. J. Nutr. Biochem. 2011;22(5):401–408.Tsianos E.V., Katsanos K. H., Tsianos V. E. Role of genetics in the diagnosis and prognosis of Crohn’s disease. World J. Gastroenterol, 2011, Vol.28, pp. 5246–5259.Tsianos E.V., Katsanos K. H., Tsianos V. E. Role of genetics in the diagnosis and prognosis of Crohn’s disease. World J. Gastroenterol, 2011, Vol.28, pp. 5246–5259.Wang T. T., Dabbas B., Laperriere D. et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J. Biol. Chem. 2010;285(4):2227–2231.Wang T. T., Dabbas B., Laperriere D. et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J. Biol. Chem. 2010;285(4):2227–2231.Waschke K. A., Villani A. C., Vermeire S. et al. Tumor necrosis factor receptor gene polymorphisms in Crohn disease: association with clinical phenotypes. Am. J. Gastroenterol, 2005, Vol.100, pp.1126–1133.Waschke K. A., Villani A. C., Vermeire S. et al. Tumor necrosis factor receptor gene polymorphisms in Crohn disease: association with clinical phenotypes. Am. J. Gastroenterol, 2005, Vol.100, pp.1126–1133.Weiss S. T. Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? J. Allergy Clin. Immunol. 2011;127(5):1128–1130.Weiss S. T. Bacterial components plus vitamin D: the ultimate solution to the asthma (autoimmune disease) epidemic? J. Allergy Clin. Immunol. 2011;127(5):1128–1130.Wu S., Liao A. P., Xia Y. et al. Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. Am. J. Pathol. 2010;177(2):686–697.Wu S., Liao A. P., Xia Y. et al. Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. Am. J. Pathol. 2010;177(2):686–697.

The authors declare that there are no conflicts of interest present.